Bolt Biotherapeutics, Inc. · NASDAQ:BOLT
Bolt Biotherapeutics — Merger or Acquisition (October 2026)
18 slides from Bolt Biotherapeutics's merger presentation, Oct 23, 2026
Slide 1: Company Transaction & Overview: Bolt Biotherapeutics and Prana Therapies
Company Transaction & Overview Bolt Biotherapeutics and Prana Therapies October 23, 2026
Slide 2: Disclosures
Disclosures This Presentation has been prepared by Bolt Biotherapeutics, Inc. ("Bolt") and Prana Therapies, Inc. ("Prana" and, together with Bolt and each of Bolt's and Prana’s subsidiaries, the "combined company") and contains information pertaining to the business and operations of the combined co
Slide 3: Bolt Biotherapeutics Announces Acquisition of Prana Therapies
The acquisition of Prana Therapies was structured as a sign-and-close reverse merger whereby all of Prana's outstanding equity interests were exchanged for a combination of shares of Bolt Biotherapeutics common stock and a newly created Series D non-voting convertible preferred stock. Concurrent wit
Slide 4: Prana Therapies: Advancing Next-Generation Multispecific Antibodies with Best-in-Disease Potential
Prana Therapies: Advancing Next-Generation Multispecific Antibodies with Best-in-Disease Potential WHOLLY-OWNED PLATFORM · LEAD PROGRAM IN PHASE 2 · CLEAR PATH TO VALUE CREATION PRA-216 Multiple Phase 2 readouts expected Q2-Q4 2027 Phase 2 Lead Program: IL-4Ra x TSLP bispecific INSPIRE Enabling a di
Slide 5: Prana's Proprietary, Wholly-Owned INSPIRE Platform
Prana’s Proprietary, Wholly-Owned, INSPIRE Platform is Designed to Power the Next Wave of Multispecific Therapeutics Elevated Clinical Outcomes Optimized PK & Dosing Clinically Validated Drug Properties Scalable Pipeline Generation Validated Biology Multi-target combinations designed to overcome eff
Slide 6: Experienced Leadership with a Proven Track Record in Biologics Innovation
Experienced Leadership with a Proven Track Record in Biologics Innovation and Value Creation Prana's Leadership Team Sheila Gujrathi Founder & Chief Executive Officer Hector Ortega Chief Medical Officer Ryan Sullivan Chief Scientific Officer Miguel Sanjuan Founder & Strategic Scientific Advisor Chri
Slide 7: Clinically Validated Platform Driving Near-Term Clinical Inflections
Clinically Validated Platform Driving Anticipated Near-Term Clinical Inflections and Potential Multi-TA Pipeline Expansion PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 IMMUNOLOGY & INFLAMMATION Atopic Disease PRA-216 IL-4Rα x TSLP Program 2 IL-31 x Undisclosed INSPIRE DISCOVERY ENGINE Multiple Discov
Slide 8: PRA-216 Is Designed for Large, Clinically Validated Markets
PRA-216 Is Designed for Large, Clinically Validated Markets With Significant Opportunity to Improve Clinical Outcomes The results are presented from different clinical trials at different points in time with different trial designs. No head-to-head trials have been conducted among the results shown
Slide 9: PRA-216 Combines Validated Alarmin and Type 2 Cytokine Pathways
PRA-216 Combines the Most Clinically Validated Alarmin and Type 2 Cytokine Pathways in Asthma and COPD Blocks alarmin-driven initiation IL-4Rα pathway TSLP pathway TARGET PRODUCT PROFILE Blocks both IL-4 and IL-13 signaling Upstream · Epithelial alarmin Downstream · Type 2 effector Greater efficacy
Slide 10: PRA-216 Potentially Differentiated on Target Biology and Exposure
PRA-216 is Potentially Differentiated on Both Target Biology and Exposure Vs. Clinical-Stage Competitors Designed for sustained target coverage with single SC Q8-12W dosing PRA-216 IL-4Rα x TSLP Designed for broad and deep pathway blockade Broad biology IL-4Rα x TSLP Extended exposure, Durable tar
Slide 11: INSPIRE Format Designed to Deliver Enhanced In Vivo PK
Prana’s INSPIRE Format is Designed to Deliver Enhanced In Vivo PK Relative to Other Formats Average parameters from individual animal fits to 2 compartment PK model Animals omitted if poor fit / suspected early ADA Molecule Format CL (mL/kg/h) Beta t1/2 (days) PRA-216 [YTE] INSPIRE 0.06 32 C’ scFv [
Slide 12: PRA-216 Favorable Safety and Tolerability Profile in Phase 1
Safety Results1 Study Schematic Phase 1 Observation Safety Findings SAEs/AESIs None Grade ≥3 TEAEs None ISRs or Local pain None Conjunctivitis None Phase 2 underway based on these promising PK, PD, and Safety Data 600mg 600mg 1200mg 600mg SAD SC MAD SC (Q2Wx3) SAD IV Double-blind, placebo-controlled
Slide 13: PRA-216 PK Profiles Demonstrated Sustained Exposure
PRA-216 Phase 1 PK Profiles Demonstrated Sustained Exposure and Support Extended Dosing Potential IV intravenous, SC subcutaneous, PK pharmacokinetic, TMDD target mediated drug disposition, LLOQ lower limit of quantification, ADA Anti-Drug Antibodies PRA-216's Exposure was High and Sustained above t
Slide 14: PRA-216 PK Exposure Profile Potentially Enables Q8-12W Maintenance Dosing
Phase 2: Will evaluate Q8W maintenance; future Q12+W regimens may be enabled by PD durability 600mg Q8W maintenance is modeled to: Exceed target exposure (clinical-response EC90) Maintain receptor occupancy at Ctrough Modeling assumes no pharmacologic synergy between the two targets Intended commerc
Slide 15: Rapid, Deep, and Durable Responses in Key Type 2 Biomarkers
50% Serum TARC 100% Blood Eosinophils 25% Serum IgE Suggests potential for Broad and Deep Type 2 inflammatory control through upstream and downstream pathway inhibition PRA-216 Demonstrated Rapid, Deep, and Durable Responses in Key Type 2 Serum and Blood Biomarkers Through Week 12 up to up to up to
Slide 16: PRA-216 Phase 1 Data Met or Exceeded Trial Objectives
PRA-216 Phase 1 Data Met or Exceeded Trial Objectives COPD Chronic Obstructive Pulmonary Disease, AD Atopic Dermatitis EoE Eosinophilic Esophagitis, NHV Normal Healthy Volunteer, PoC Proof of Concept, ADA Anti-drug Antibodies GOAL Demonstrate differentiated bispecific PK profile Results Potential Be
Slide 17: Prana Therapies: Best-in-Disease Potential and Expected Catalysts
Prana Therapies: Advancing Next-Generation Multispecific Antibodies with Best-in-Disease Potential WHOLLY-OWNED PLATFORM · LEAD PROGRAM IN PHASE 2 · CLEAR PATH TO VALUE CREATION PRA-216 Multiple Phase 2 readouts expected beginning Q2-Q4 2027 Phase 2 Lead Program: IL-4Ra x TSLP bispecific INSPIRE Ena
Slide 18: Therapies
THERAPIES
Bolt Biotherapeutics — Merger or Acquisition (October 2026) on 6ix